2-(2,2-dimethylpropionyl)-7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-1,2,3,4-tetrahydroisoquinoline-(3S)-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2,2-dimethylpropionyl)-7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-1,2,3,4-tetrahydroisoquinoline-(3S)-carboxylic acid
• 英文别名: 2-(2,2-dimethylpropanoyl)-7-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-3,4-dihydro-1H-isoquinoline-1-carboxylic acid
• 化学式: C₂₇H₃₀N₂O₅
• 分子量: 462.546
• InChiKey: HXNFHIYLWBBKCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  92.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  四氢糠醇 、 aqueous lithium hydroxide 、 methyl 7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-1,2,3,4-tetrahydroisoquinoline-(3S)-carboxylate 、 三甲基乙酰氯 生成 2-(2,2-dimethylpropionyl)-7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-1,2,3,4-tetrahydroisoquinoline-(3S)-carboxylic acid
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Novel heterocyclic compounds and salts thereof and medicinal use of the same
  申请人：——

  公开号：US20030027836A1

  公开（公告）日：2003-02-06

  A heterocyclic compound of the formula [I] 1 wherein R 1 is hydrogen atom or lower alkyl, R 2 is hydrogen atom, alkyl optionally having a substituent and the like, R 3 is hydrogen atom, lower alkyl and the like, A is a single bond or >N—R 5 wherein R 5 is hydrogen atom or lower alkyl, B is lower alkylene, and Y is aryl optionally having a substituent and the like, and a pharmaceutically acceptable salt thereof show a hypoglycemic action, a blood hypolipidemic action, an insulin resistance-improving action and a PPAR activating action, and are useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complication, a glucose tolerance improver, an anti-atherosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated disease and an agent for the prophylaxis or treatment of syndrome X.

  一种具有下列化学式[I]的杂环化合物，其中R1是氢原子或较低的烷基，R2是氢原子，烷基或可选地具有取代基等，R3是氢原子，较低的烷基等，A是单键或>N—R5，其中R5是氢原子或较低的烷基，B是较低的亚烷基，Y是芳基或可选地具有取代基等，以及其药学上可接受的盐具有降血糖作用、降血脂作用、改善胰岛素抵抗作用和PPAR激活作用，并且可用作降血糖剂、降血脂剂、改善胰岛素抵抗剂、糖尿病治疗剂、糖尿病并发症治疗剂、葡萄糖耐量改善剂、抗动脉粥样硬化剂、抗肥胖剂、抗炎剂、预防或治疗PPAR介导疾病的药剂和预防或治疗X综合征的药剂。
• NOVEL HETEROCYCLIC COMPOUNDS AND SALTS THEREOF AND MEDICINAL USE OF THE SAME
  申请人：Kyoto Pharmaceutical Industries, Ltd.

  公开号：EP1236719A1

  公开（公告）日：2002-09-04

  A heterocyclic compound of the formula [I] wherein R1 is hydrogen atom or lower alkyl, R2 is hydrogen atom, alkyl optionally having a substituent and the like, R3 is hydrogen atom, lower alkyl and the like, A is a single bond or >N-R5 wherein R5 is hydrogen atom or lower alkyl, B is lower alkylene, and Y is aryl optionally having a substituent and the like, and a pharmaceutically acceptable salt thereof show a hypoglycemic action, a blood hypolipidemic action, an insulin resistance-improving action and a PPAR activating action, and are useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complication, a glucose tolerance improver, an anti-atherosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated disease and an agent for the prophylaxis or treatment of syndrome X.

  式[I]的杂环化合物 其中R1为氢原子或低级烷基，R2为氢原子、可选具有取代基等的烷基，R3为氢原子、低级烷基等，A为单键或>N-R5，其中R5为氢原子或低级烷基，B为低级亚烷基，Y为可选具有取代基等的芳基，及其药学上可接受的盐具有降血糖作用、降血脂作用、胰岛素抵抗改善作用和PPAR激活作用，可用作降血糖剂、降血脂剂、胰岛素抵抗改善剂和PPAR激活剂、可用作降血糖剂、降血脂剂、胰岛素抵抗改善剂、糖尿病治疗剂、糖尿病并发症治疗剂、葡萄糖耐量改善剂、抗动脉粥样硬化剂、抗肥胖剂、抗炎剂、预防或治疗 PPAR 介导的疾病的药物以及预防或治疗 X 综合征的药物。
• US6589963B2
  申请人：——

  公开号：US6589963B2

  公开（公告）日：2003-07-08